Canopy Growth: Insider Tax Sales Mask a Bigger Bet on US Legalization

Canopy Growth shares fell 5% after directors sold shares, but the real catalyst is the DEA's cannabis rescheduling hearing. Insider buying over 12 months signals confidence.

The stock slipped more than 5% on Wednesday to €0.82 after a regulatory filing revealed that several directors had trimmed their holdings. But the sell-off may be overdone. Theresa Yanofsky and David Angelo Lazzarato together offloaded roughly 38,000 shares at $0.92 each — a transaction that, on closer inspection, reflects nothing more than a routine tax obligation tied to equity grants issued in mid-June. These are not panic exits.

The real narrative driving Canopy Growth today is not boardroom movements but a regulatory clock ticking in Washington. The Drug Enforcement Administration launched its formal hearing on the rescheduling of cannabis on June 29, 2026, with a conclusion expected by mid-July. The outcome will determine whether Canopy can finally execute its long-awaited entry into the US market — the linchpin of its entire "Canopy USA" strategy.

The numbers behind the noise

The company’s latest quarter offered some genuine momentum. Revenue for the final period of fiscal 2026 hit $71.2 million, pushing full-year sales up 6%. Medical cannabis in Canada jumped 27% in the quarter, while international receipts surged 68%. Yet the core problem remains: profitability. The adjusted operating loss for the full year came in at $20.2 million — a 14% improvement, but still a deficit.

A net loss of $154.72 million in the most recent quarter underscores the scale of the challenge. Still, free cash burn shrank to roughly $69 million, and the balance sheet shows net liquidity of $131.3 million. That cushion gives management time, but it does not erase an accumulated deficit of C$11 billion.

Insider behavior over a longer horizon tells a more confident story. Over the past twelve months, executives and major shareholders have bought $23.1 million worth of stock while selling just $769,200 — a buy-to-sell ratio that suggests conviction in the DEA pivot.

Two paths, one very narrow window

A clean rescheduling verdict would remove a major structural headwind by eliminating the punitive 280E tax burden that weighs on all US cannabis operators. The bull case sees Canopy Growth capturing full US market access and swinging to positive adjusted EBITDA in fiscal 2027 — a target the board has explicitly laid out. Technical support exists too: the RSI sits at a neutral 50, and the 50-day moving average at $0.92 offers an immediate upside target. The 200-day line at $1.00 sits about 13.5% above the current price.

The bear case is equally stark. Delays or an inconclusive hearing could send the stock sliding toward its 52-week low of $0.75 — a further 16% drop from Wednesday’s close. Even if rescheduling goes through, cash-flow problems will not vanish overnight. Analysts expect next-quarter revenue of $58.52 million, a 12.25% sequential increase. Missing that number would push the profitability target further out of reach.

Waiting on Washington, watching the charts

The stock has lost nearly 20% since the start of the year and trades well below both key moving averages. With annualized 30-day volatility of roughly 31%, every headline from the DEA hearing will move the needle — and none more so than the official recommendation due by mid-July.

The next hard data point arrives in August 2026, when Canopy reports its fiscal first-quarter results. Until then, the market is pricing in caution: the stock sits about 5% under the 50-day average, signalling that investors want proof before they pay for hope. The insider tax sales may have rattled sentiment, but the real show is in Washington.